CJC-1295 vs Tesamorelin — Comparing Two GHRH Analogues

CJC-1295 (no DAC) and Tesamorelin share the same proximal target — the pituitary growth hormone-releasing hormone receptor (GHRHR) — yet they differ in sequence length, pharmacokinetics, evidence depth, regulatory standing, and the research questions each is best positioned to answer. Both are synthetic peptide analogues of endogenous GHRH, both require subcutaneous administration, and both are unapproved in the United Kingdom. Beyond those shared features, the comparison reveals two quite different tools. This page maps the mechanistic differences, the evidence base behind each compound, and the research contexts where one holds an advantage over the other.

Research context only. Neither compound is approved for human use in the UK or EU. Nothing on this page constitutes medical advice. All protocols and dosing figures reflect published preclinical and clinical-trial literature.

Structural and pharmacokinetic differences

The most fundamental difference between the two peptides is their sequence length and the modification strategy used to protect each from rapid plasma degradation.

CJC-1295 no-DAC (Mod GRF 1-29) is a twenty-nine amino acid analogue of the N-terminal active fragment of native GHRH. The four strategic amino acid substitutions — at positions two, eight, fifteen and twenty-seven of the native GHRH sequence — protect critical peptide bonds from dipeptidyl peptidase IV (DPP-IV) cleavage and extend the effective plasma half-life from the roughly two-minute lifespan of unmodified GHRH(1-29) to approximately twenty-five to thirty minutes [PMID:16352683]. The resulting pharmacokinetic profile is clean and pulse-compatible: each subcutaneous injection generates a single, clearly delineated GHRHR activation event, and plasma concentrations return to near baseline before the next dose is administered.

Tesamorelin retains the full forty-four amino acid sequence of native GHRH and adds a trans-3-hexenoyl fatty acid moiety to the N-terminus. This modification protects the N-terminal glutamine residue that is the primary DPP-IV cleavage site in intact GHRH, extending plasma half-life to approximately twenty-six minutes — comparable to CJC-1295 no-DAC in terms of plasma kinetics [PMID:18057338]. The pharmacological distinction lies downstream of plasma clearance: because Tesamorelin engages the full GHRH receptor with the complete ligand, the downstream intracellular cAMP cascade and subsequent GH secretory wave are more sustained than those produced by the shorter truncated analogue. Single evening injections generate a prolonged amplification of the nocturnal GH pulse rather than the sharp, rapidly resolved peak seen with CJC-1295 no-DAC. The net effect is that Tesamorelin produces a sustained GH signal within the physiological pulsatile framework, whereas CJC-1295 no-DAC produces a series of sharper, more discrete pulses when dosed multiple times daily.

GH pulse architecture — the core mechanistic distinction

The concept of GH pulsatility is central to choosing between these two compounds in a research context.

Under normal physiology, hypothalamic GHRH drives four to nine discrete GH secretion events per day in healthy adults, each separated by a trough where circulating GH is near undetectable. This pulse-and-trough architecture is not incidental — it is functionally important for maintaining hepatic GH receptor sensitivity, sustaining appropriate IGF-1 production, and preventing the receptor downregulation that follows continuous GH-axis stimulation. Preserving the trough between pulses is what distinguishes GHRH-based secretagogue research from direct exogenous GH administration, which produces a flat, continuous supraphysiological elevation with attendant receptor desensitisation and insulin resistance risk.

CJC-1295 no-DAC, dosed three times daily at one hundred micrograms per injection, fires three discrete GHRHR activation events. Rapid plasma clearance between injections allows pituitary somatotrophs to recover sensitivity before the next dose arrives. Each pulse amplifies the natural GH release that would have occurred at that point in the endogenous cycle. Research by Ionescu and Frohman confirmed that pulsatile GH secretion persists even under repeated GHRH-receptor stimulation when the agonist is cleared rapidly between doses [PMID:16984995]. This makes CJC-1295 no-DAC the preferred tool in protocols where GH pulse amplitude, frequency, and the physiological trough-to-peak ratio are variables of experimental interest.

Tesamorelin, dosed once daily in the evening, produces a broader, more sustained GHRHR activation that amplifies primarily the nocturnal GH secretory window. The signal is still pulsatile in the sense that somatostatin-mediated negative feedback remains operative, but the amplitude and duration of each post-injection GH secretory event are greater and more prolonged than with the shorter analogue. Phase III data from Falutz et al. demonstrated that this once-daily sustained activation pattern is sufficient to drive approximately fifteen to eighteen percent reductions in visceral adipose tissue (VAT) versus baseline and approximately thirty percent versus placebo after twenty-six weeks of treatment [PMID:18057338]. The sustained signal appears particularly effective at driving VAT-selective lipolysis — a finding that has not been systematically replicated with CJC-1295 no-DAC at equivalent cycle lengths.

Evidence depth — a clear asymmetry

The evidentiary asymmetry between these two compounds is substantial and should inform research-design decisions.

CJC-1295 no-DAC rests on Phase I pharmacokinetic data and a comparatively limited clinical evidence base. Teichman et al. characterised the PK profile of the DAC-modified CJC-1295 variant in healthy adults, demonstrating sustained IGF-1 elevation and dose-dependent GH responses [PMID:16352683]. Jetté et al. confirmed GHRHR activation and downstream GH signalling in rodent models [PMID:15817669]. Alba et al. demonstrated normalisation of growth in GHRH-knockout mice with monthly CJC-1295 administration [PMID:16849630]. The compound never advanced to Phase III and has no approved indication in any jurisdiction. Published human PK data relate predominantly to the DAC variant; data for the no-DAC form in controlled human studies are limited.

Tesamorelin carries the most extensive clinical evidence base of any GHRH-class peptide in current research circulation. The pivotal NEJM Phase III publication by Falutz et al. (2007) enrolled over four hundred HIV-positive subjects with abdominal fat accumulation in a randomised, double-blind, placebo-controlled trial, confirming significant VAT reduction, triglyceride improvement, and a favourable safety profile at Tesamorelin two milligrams daily over twenty-six weeks [PMID:18057338]. A subsequent JAIDS extension study by the same group confirmed durability and characterised the partial VAT rebound that follows discontinuation [PMID:20101189]. Stanley et al. published mechanistic sub-studies linking Tesamorelin-driven VAT reduction to hepatic fat fraction reduction and improved inflammatory markers including C-reactive protein and interleukin-6, measured by MRS and standard immunoassay [PMID:21625541]. A further JAMA publication from Stanley's group at Massachusetts General Hospital confirmed liver fat reduction alongside VAT effects in a dedicated hepatic sub-study [PMID:25038357]. Fourman et al. subsequently documented significant improvements in liver enzymes (ALT/AST) at twenty-six weeks in HIV-positive subjects [PMID:28692534]. This clinical programme resulted in FDA approval of EGRIFTA in 2010 — making Tesamorelin the only GHRH analogue to achieve regulatory approval anywhere in the world.

Dosing comparison

The dosing schedules reflect the pharmacokinetic profiles of each compound and the research objectives they are designed to serve.

CJC-1295 no-DAC is typically administered at one hundred micrograms per injection, three times daily by subcutaneous injection — commonly timed to a pre-fasted morning window, a pre-workout or mid-afternoon window, and immediately before sleep. The three-injection cadence is designed to amplify the three largest physiological GH secretory events within a twenty-four-hour period. Research cycle durations of eight to twelve weeks are standard. Co-administration with ipamorelin at two hundred to three hundred micrograms per injection is the most extensively documented combination in pre-clinical research and produces synergistic GH release beyond either compound alone — a convergence at the pituitary level where GHRHR agonism (CJC-1295) and ghrelin-receptor agonism (ipamorelin) simultaneously prime and trigger somatotroph exocytosis through non-competing intracellular pathways.

Tesamorelin is administered at one to two milligrams once daily by subcutaneous injection, with evening administration preferred to align with the nocturnal physiological GH secretory peak. The FDA-approved dose for HIV-lipodystrophy is two milligrams daily; research protocols outside this indication frequently use the same dose range. Cycle durations of twelve weeks or longer are typical — Phase III data were collected at twenty-six weeks, and the VAT-reduction plateau in published studies is reached progressively over three to six months. AOD-9604 (the GH C-terminal lipolytic fragment) is the most mechanistically coherent companion compound when visceral fat is the primary research endpoint, given its direct adipocyte HSL-mediated lipolytic action that operates independently of the GHRHR axis and is therefore additive rather than redundant to Tesamorelin's upstream effect [PMID:10950816].

Regulatory standing in 2026

CJC-1295 no-DAC is an unapproved research compound in the United Kingdom, United States, and European Union. It is not scheduled under the Misuse of Drugs Act 1971 and is not classified as a psychoactive substance. Supply for human administration constitutes supply of an unlicensed medicinal product under the Human Medicines Regulations 2012 and requires MHRA authorisation that is not currently available for this compound. Laboratory research institutions may hold it under "not for human use" protocols.

Tesamorelin holds FDA approval (as EGRIFTA and Egrifta SV) for the specific indication of HIV-associated lipodystrophy — the only GHRH analogue to achieve this status. It has not received MHRA or EMA marketing authorisation. UK availability outside of a licensed clinical trial or import via named-patient exemption is therefore restricted. For any research application outside the HIV-lipodystrophy indication, even in jurisdictions where EGRIFTA is commercially available, Tesamorelin use is off-label and investigational.

Choosing between CJC-1295 no-DAC and Tesamorelin

The decision rests on the specific research question and endpoint of interest.

CJC-1295 no-DAC is better suited when: the research protocol requires multiple discrete GH pulses per day; GH pulsatility architecture is a primary outcome variable; the compound will be co-administered with ipamorelin for synergistic pituitary activation; or the research objective centres on body-recomposition endpoints where pulse amplitude and frequency are believed to be mechanistically important variables. The shorter cycle length (eight to twelve weeks) and lower per-dose quantity also simplify logistics in preclinical model settings.

Tesamorelin is better suited when: visceral adipose tissue volume reduction is the primary endpoint; the research protocol requires the deepest available published evidence base to contextualise findings; hepatic fat fraction or inflammatory-marker co-endpoints are included; or the once-daily dosing simplicity of a sustained-signal GHRH analogue is operationally preferable to a three-times-daily injection schedule. The FDA-approval evidence base for VAT reduction makes Tesamorelin the reference compound for any research comparing a novel intervention against an established GHRH-axis benchmark.

Both compounds can be combined with each other in advanced somatotropic research protocols — the CJC-1295 + Ipamorelin + Tesamorelin GH Stack explores this three-way combination, using CJC-1295 no-DAC to provide pulsatile GHRHR activation, ipamorelin to trigger each pulse through ghrelin-receptor co-agonism, and Tesamorelin to provide a sustained evening GHRHR signal targeting the nocturnal secretory window.

Related stacks

For researchers investigating visceral fat endpoints with Tesamorelin as the primary compound, the Tesamorelin + AOD-9604 Visceral Fat Stack pairs the FDA-approved GHRH analogue with the GH C-terminal lipolytic fragment AOD-9604. The combination addresses visceral adipolysis through dual mechanisms — upstream GHRH-axis activation and direct peripheral adipocyte lipolysis — without IGF-1 supra-elevation risk.

For researchers focusing on body-recomposition protocols that prioritise pulsatile GH amplification and tissue-repair co-support, the Ipamorelin + CJC-1295 + BPC-157 Recomp Stack extends the CJC-1295 no-DAC and ipamorelin pairing with BPC-157, a systemically active pentadecapeptide with documented connective-tissue and gut-healing activity in rodent models — adding a peripheral repair signal to the central somatotropic axis stimulation provided by the GHRH and GHRP components.

For a full somatotropic axis protocol combining both GHRH-analogue approaches with a selective GHRP pulse trigger, see the CJC-1295 + Ipamorelin + Tesamorelin GH Stack, which examines the mechanistic rationale and research protocol for using all three compounds concurrently across a twelve-week cycle.

Verdict — research-question matching

CJC-1295 no-DAC is the stronger choice when preserving natural GH pulsatility is the research objective — multi-injection daily dosing fires discrete somatotroph activation events, restores trough-to-peak amplitude, and pairs synergistically with ipamorelin at the pituitary. Tesamorelin is the evidence-heavier option when visceral adipose tissue reduction is the primary endpoint: its Phase III FDA-approval evidence base is unmatched among GHRH analogues, and once-daily evening dosing supports sustained axis activation with a documented VAT-selective lipolytic effect. Researchers focused on body-recomposition and GH pulse architecture will typically favour CJC-1295 no-DAC, ideally within the [CJC-1295 + Ipamorelin + Tesamorelin GH Stack](/stacks/cjc-1295-ipamorelin-tesamorelin-gh-stack). Those with visceral-fat or hepatic-fat endpoints will find Tesamorelin better evidenced, especially combined with AOD-9604 in the [Tesamorelin + AOD-9604 Visceral Fat Stack](/stacks/tesamorelin-aod-9604-visceral-fat-stack).